Comparison of selective plasma exchange and plasmadialfiltration with MARS and Prometheus systems in the treatment of liver failure

The mortality of patients with hepatic failure remains high. Often the patient's life can be saved only with extracorporeal liver support (ELS). ELS systems – MARS^® и Prometheus^® have proved their efficacy but their widespread use is constrained by their very high cost. Introduction in clinical practice of new affordable ELS systems is a topical issue.
The objective: to compare clinical and laboratory effects of selective plasma exchange (SPE), plasmadialfiltration (PDF) with use of the selective membrane plasma separators EvaclioTM and MARS^® and Prometheus^® (FPSA) systems in the treatment of liver failure.
Subjects and methods: 15 extracorporeal procedures of each type were performed in 52 patients with acute liver failure (14) and acute-on-chronic liver failure (38): MARS, FPSA, PDF, SPE with use of Evaclio ЕС-2C, and ЕС-3C, ЕС-4C. The clinical and laboratory parameters (total, direct and indirect bilirubin, total protein, albumin, creatinine, urea, etc.), severity of the condition according to MELD score were determined before and after the session and the next morning. Changes, side effects and complications of procedures were assessed and compared.
Results. Reduction of concentration of direct bilirubin was comparable with FPSA, PDF and SPE on Evaclio ЕС-3C20 и ЕС-4C20 (38-42%), indirect bilirubin – with PDF and SPE on Evaclio ЕС-3C20 и ЕС-4C20 (29-34%). Low-molecular metabolites (urea, creatinine) were better removed with FPSA (35-44%) and PDF (40-42%). The reduction of their concentration with SPE was insignificant. The reduction of albumin level was the highest with FPSA (10.2%) and SPE on Evaclio ЕС-4C20 (14.3%). All investigated ELS methods did not exert a significant influence on the basic parameters of blood coagulation and quantity of blood cells. No side effects and complications were observed.
Conclusion: Selective plasma exchange and plasmadiafiltration are generally comparable in clinical and laboratory effects in the treatment of liver failure with MARS and Prometheus system provided significantly lower costs.

1. Polushin Yu.S., Sokolov D.V., Belousov D.Yu. et al. Pharmacoeconomic assessment of intermittent and continuous renal replacement therapy. Messenger of Anesthesiology and Resuscitation, 2017, vol. 14, no. 6, pp. 6-20. (In Russ.)

2. Order No. 804n by the Russian Ministry of Health as of October 13, 2017 On Approval of Medical Services Nomenclature. (In Russ.)

3. Tariff agreement for the payment of medical care provided under the territorial program of mandatory medical insurance of the city of Moscow for 2020 dated 30.12.2019. Appendix No. 8.2. (In Russ.)

4. Ekstrakorporalnaya gemokorrektsiya: terminologiya, yazykovye sootvetstviya: Metodicheskie rekomendatsii NP Natsionalnoe obschestvo spetsialistov v oblasti gemafereza i ekstrakorporalnoy gemokorrektsii. [Extracorporeal hemocorrection: terminology, language correspondences: Methodological recommendations of NP National Society of Specialists in the Field of Hemapheresis and Extracorporeal Blood Correction]. Moscow, St. Petersburg, 2016, 36 p.

5. Banares R., Nevens F., Larsen F.S. et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology, 2013, vol. 57, no. 3, pp. 1153-1162.

6. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J. Hepatology, 2017, vol. 66, pp. 1047-1081.

7. Hanish S., Stein D.M., Scalea J.R. et al. Molecular adsorbent recirculating system evectively replaces hepatic function in severe acute liver failure. Ann. Surg., 2017, vol. 266, no. 4, pp. 677-684.

8. Hernaez R., Sola E., Moreau R. et al. Acute-on-chronic liver failure: an update. Gut, 2017, vol. 66, pp. 541‒553. doi: 10/1136/gutjnl-2016-312670.

9. Ho D., Fan S.T., To J. et al. Selective plasma filtration for treatment of fulminant hepatic failure induced D-galactosamine in pig model. Gut, 2002, vol. 50, pp. 869-876.

10. https://rustransplant.com/kolichestvo-transplantacij-pecheni.

11. Kribben A., Gerken G., Haag S. et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology, 2012, vol. 142, no. 4, pp. 782–789.e3.

12. Li M., Xue J., Liu J. et al. Efficacy of cytokine removal by plasmadiafiltration using a selective plasma separator: in vitro sepsis model. Ther. Apher. Dial., 2010, vol. 15, no. 1, pp. 98-104.

13. Moreau R., Jalan R., Gines P. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology, 2013, vol. 144, pp. 1426-1437.

14. Mori T., Eguchi Y., Schimizu T. et al. A case of acute hepetic insufficiency treated with novel plasmapheresis plasma diafiltration for bridge use until liver transplantation. Ther. Apher. Dial., 2002, vol. 6, no. 6, pp. 463-466.

15. Morris C., Rogerson D. The use of high-flux albumin haemofiltration (HFAF) with Evaclio EC-2C in the management of liver failure as a bridge to transplantation. J. Intens. Care Soc., 2011, vol. 12, no. 3, pp. 228-233.

16. Ohkubo A., Okado T., Kurashima N. et al. Removal characteristics of immunoglobulin g subclasses by conventional plasma exchange and selective plasma exchange. Ther. Apher. Dial., 2015, vol. 19, no. 4, pp. 361-366.

17. Padmanabhan A., Connelly-Smith L., Aqui N. et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J. Clin. Apher., 2019, vol. 34, pp. 171‒354. doi: 10.1002/jca.21705.

18. Ronco C., Bellomo R. Principles of solute clearance during continuous renal replacement therapy. Crit. Care Nephrology, 1998, Dordrecht, The Netherlands: Kluwer Academic Publishers. pp. 1213-1223.

19. Senturk E., Esen F., Ozcan P.E. et al. The treatment of acute liver failure with fractionated plasma separation and adsorption system: experience in 85 applications. J. Clin. Apher., 2010, vol. 25, no. 4, pp. 195-201.

20. Taniguchi K., Miyahara T. EVACURETM – Membrane Plasma Separator with Unique Permeability Properties. Med. Sci. Digest, 2002, vol. 28, no. 6, pp. 29-33.

21. Yamamoto H., Nakae H., Uji Y. et al. Plasma adiponectin levels in acute liver failure patients treated with plasma filtration with dialysis and plasma exchange. Ther. Apher. Dial., 2015, vol. 19, no. 4, pp. 349-354.